De Sanctis Juan B, Mijares Michael, Suárez Alírica, Compagnone Reinaldo, Garmendia Jenny, Moreno Dolores, Salazar-Bookaman Margarita
Instituto de Inmunología, Facultad de Medicina, Universidad Central de Venezuela, Caracas, Venezuela.
Recent Pat Inflamm Allergy Drug Discov. 2010 Jun;4(2):144-8. doi: 10.2174/187221310791163026.
Thalidomide and its immunomodulatory imide drugs (IMiDs) analogues CC-5013 (Revlimid, Lenalidomide) and CC-4047 (Actimid, Pomalidomide) have been used as anti-inflammatory and anticancerous drugs in the recent years. Thalidomide and IMiDs inhibit the cytokines tumour necrosis factor-alpha (TNF-alpha), interleukins (IL) 1-beta, 6, 12, and granulocyte macrophage-colony stimulating factor (GM-CSF). They also costimulate primary human T, NKT and NK lymphocytes inducing their proliferation, cytokine production, and cytotoxic activity. On the other hand, the compounds are anti-angiogenic, anti-proliferative, and pro-apoptotic. Thalidomide analogues have been used as inhibitors of alpha glucosidase and could be potential drugs for diabetes treatment. In this review, we explore the current trend of the different structures, the new patents, and the possible new applications in different pathologies.
沙利度胺及其免疫调节性酰亚胺药物（IMiDs）类似物CC - 5013（来那度胺，Revlimid）和CC - 4047（泊马度胺，Actimid）近年来已被用作抗炎和抗癌药物。沙利度胺和IMiDs可抑制细胞因子肿瘤坏死因子-α（TNF-α）、白细胞介素（IL）1-β、6、12以及粒细胞巨噬细胞集落刺激因子（GM-CSF）。它们还能共刺激原代人T细胞、NKT细胞和NK淋巴细胞，诱导其增殖、细胞因子产生及细胞毒性活性。另一方面，这些化合物具有抗血管生成、抗增殖和促凋亡作用。沙利度胺类似物已被用作α-葡萄糖苷酶抑制剂，可能成为治疗糖尿病的潜在药物。在本综述中，我们探讨了不同结构的当前趋势、新专利以及在不同病理情况下可能的新应用。
